Analyse Rafael Holdings, Inc. (RFL) — Kairos Score 51/100

À propos de Rafael Holdings, Inc.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Rafael Holdings, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur RFL dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur RFL.

• Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
• Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.